Home Therapy in Virginia

Zida LLC manufactures the Zida Control Sock, a FDA-cleared neuromodulation device for at-home treatment of overactive bladder (OAB) and associated urinary symptoms including urge incontinence, urinary frequency, and nocturia. The device uses patented embedded nano-electronics to deliver percutaneous tibial nerve stimulation (PTNS), accessing the tibial nerve at the ankle region to modulate sacral nerve function and regulate bladder control. Clinical data demonstrates over 70% reduction in incontinence episodes. Treatment protocol requires 12 sessions administered once weekly for 30 minutes each. The device is unisex, non-invasive, has no serious side effects, and requires no drug interactions. Zida products are prescribed through US physicians and covered by major insurers including Medicare, Cigna, and Blue Cross. The company serves urology practices, continence clinics, and patients across all age groups seeking non-pharmacological, non-surgical bladder dysfunction management.

Kaléo is a pharmaceutical company specializing in drug-device combinations, particularly innovative auto-injector systems. Founded by twin brothers Eric and Evan Edwards and based in Glen Allen, Virginia, Kaléo designs and manufactures auto-injectors for urgent medical conditions with an emphasis on patient safety, ease of use, and reliability. The company's proprietary Aerio™ platform leverages Human Factors Engineering and fully automated manufacturing to deliver precision drug-delivery devices adaptable across multiple disease categories and environments. Kaléo's marketed portfolio includes AUVI-Q® (epinephrine auto-injector for severe allergies), naloxone auto-injectors for opioid overdose response, and medical countermeasures for nerve agent exposure and chemical threats. The company partners with pharmaceutical manufacturers and government agencies to develop custom drug-delivery solutions and maintains a strong commitment to patient access through financial assistance programs. With approximately 155 issued or pending patents, Kaléo serves both civilian healthcare markets and specialty applications including emergency medicine and global health security.